Combating COVID-19: Identifying a potential drug candidate for human testing in 90 days
- This event has passed.
Dr. Bo Barnhart, AbCellera, will present on the technology and details of AbCellera’s work around the discovery of an antibody therapeutic for COVID-19.
About the presenter:
Bo Barnhart, Ph.D. leads antibody developability and lead optimization at AbCellera. He brings his expertise to help partners evaluate, optimize and nominate developable lead candidates from the large panels of high-quality antibodies generated by AbCellera. Bo has over 12 years of antibody drug development experience in the pharmaceutical industry. Before joining AbCellera, he was a Senior Director at Bristol-Myers Squibb, where he progressed more than ten therapeutics, spanning target identification up to early clinical development, with several entering first-in-human testing. Bo’s experience in leading antibody programs also includes antibody engineering and developability evaluation as well as building and testing translational hypotheses. Prior to entering industry, he was a postdoctoral fellow at the University of Pennsylvania. He completed his PhD in Immunology at the University of Chicago and his BA in Biology and English Literature at Rutgers University.